Effects of Psilocybin in Advanced-Stage Cancer Patients With Anxiety

NCT ID: NCT00302744

Last Updated: 2025-03-13

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE1/PHASE2
• Total Enrollment: 12 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2004-04-30
• Study Completion Date: 2008-12-31

Brief Summary

Psychiatric Research Study For Cancer Patients

The Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center is conducting a study designed to measure the effectiveness of the novel psychoactive medication psilocybin on the reduction of anxiety, depression, and physical pain.

Detailed Description

The significance of this study is that it is addressing the important issues of psychological and spiritual well being of people who have advanced cancer. In 2001, the National Cancer Policy Board of the Institute of Medicine and National Research Council issued a report (Improving Palliative Care for Cancer: Summary and Recommendations) that specifically recommended research be conducted using novel agents and methods. Psilocybin is a novel agent which produces a profound alteration in your state of consciousness. It is the main active ingredient found in "magic mushrooms".

Our specific aim is to learn whether this psychoactive drug, psilocybin, might be effective in reducing anxiety, depression and physical pain, and therefore improving your quality of life. This pilot study will start with 12 people ages 18-70. For each participant there will be two overnight admissions to the hospital. In one session you will be given a placebo and in the other you will get the active medication, but no one will know which drug is administered when. This is called a double blind study. You will be asked to fill out questionnaires about how you feel, your pain levels and your moods. There will also be at least two psychotherapy meetings before the study sessions, so that you are fully aware of what to expect and to have all your questions answered.

We cannot take you in the study if you have central nervous system (CNS) cancers, kidney disease, diabetes, abnormal liver function tests, epilepsy, cardiovascular disease including untreated high blood pressure (BP greater than 140/90), and pregnancy. The psychiatric exclusions are: you or an immediate family member with a history of a major psychiatric disorder, a current substance abuse problem, or an anxiety or a mood disorder within 1 year prior to the onset of symptoms of your current illness.

We also cannot take you in the study if you are taking certain medications, such as: anti-seizure, insulin and oral hypoglycemics, and cardiovascular drugs (except anti-hypertensive medications). Some antidepressant (SSRIs) medications cannot be taken within the two weeks prior to the session (except for Prozac, which cannot be taken in the last 5 weeks prior to the session).

You will get a MRI of the brain prior to admission (if you haven't had one in the prior two months), at the study's expense, to be sure there is no CNS involvement. You can provide us, or the study will pay for, lab work from the prior 2 weeks (CBC, liver function and renal function). The history and physical, neurological exam, EKG, and a urine pregnancy test (if you are a woman with child-bearing potential), will be done on admission by the house staff doctors.

You will be allowed to take your own medications while in the hospital, and will be encouraged to bring to the hospital personal photos, small memorabilia, and some of your favorite music that can be played during the sessions.

Conditions

Anxiety

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: QUADRUPLE

Study Groups

Psilocybin

Single, 6-hour treatment with 0.2 mg/kg active psilocybin capsule.

Group Type: EXPERIMENTAL

Psilocybin (drug)

Intervention Type: DRUG

Capsule (.2 mg/kg).

MRI

Intervention Type: DIAGNOSTIC_TEST

MRI required for study inclusion for purpose of ruling out metasteses to brain

Active Niacin Placebo

Each subject functioned as their own control, receiving niacin placebo capsule in a single 6-hour session.

Group Type: ACTIVE_COMPARATOR

Niacin

Intervention Type: OTHER

Active Placebo

MRI

Intervention Type: DIAGNOSTIC_TEST

MRI required for study inclusion for purpose of ruling out metasteses to brain

Interventions

Psilocybin (drug)

Capsule (.2 mg/kg).

Intervention Type: DRUG

Niacin

Active Placebo

Intervention Type: OTHER

MRI

MRI required for study inclusion for purpose of ruling out metasteses to brain

Intervention Type: DIAGNOSTIC_TEST

Other Intervention Names

4-phosphoryloxy-N,N-dimethyltryptamine; nicotinamide; vitamin B3

Eligibility Criteria

Inclusion Criteria

• Have advanced-stage cancer and anxiety.
• Be between the ages of 18 - 70.

Note: The location for the two treatment sessions is Los Angeles, California. Treatment sessions are scheduled three to six weeks apart, and they include one overnight hospital stay both times.

Exclusion Criteria

• Not have cancer that affects the central nervous system or brain function.
• Have no history of major psychiatric disorder.
• Have no kidney disease, abnormal liver functions, epilepsy, or cardiovascular disease, including untreated hypertension.
• Not be taking insulin, oral hypoglycemic, anti-seizure, or cardiovascular medications (except anti-hypertensive drugs).
• May take PRN benzodiazepines up to 3 days before the session.
• No Prozac for the previous 5 weeks.
• No medications the day of and the day after treatment sessions, except may take ongoing adjuvant chemotherapy as prescribed, prescribed or over-the-counter non-narcotic pain medication at any time, and narcotic pain medications up to eight hours before administration of psilocybin and six hours after administration.
• No alcohol consumption the day before, the day of, and the day after a session.
• Female subjects of childbearing potential must have a negative pregnancy test and agree to use an effective form of birth control.

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 70 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Heffter Research Institute

OTHER

Sponsor Role: collaborator

Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center

OTHER

Sponsor Role: lead

Responsible Party

Charles S. Grob, M.D.

professor of psychiatry

Responsibility Role: PRINCIPAL_INVESTIGATOR

Principal Investigators

Charles S. Grob, MD

Role: PRINCIPAL_INVESTIGATOR

University of California, Los Angeles

Locations

Harbor-UCLA Medical Center

Torrance, California, United States

Countries

United States

References

Grob CS, Danforth AL, Chopra GS, Hagerty M, McKay CR, Halberstadt AL, Greer GR. Pilot study of psilocybin treatment for anxiety in patients with advanced-stage cancer. Arch Gen Psychiatry. 2011 Jan;68(1):71-8. doi: 10.1001/archgenpsychiatry.2010.116. Epub 2010 Sep 6.

Reference Type: RESULT

PMID: 20819978 (View on PubMed)

Other Identifiers

HEFFTER11287-01

Identifier Type: -

Identifier Source: org_study_id